

Date: 05 February 2026

To	The Secretary
The Secretary	The Secretary
BSE Limited	The National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers	Exchange Plaza, Plot No. C/1 G Block
Dalal Street	Bandra -Kurla Complex, Bandra (East)
Mumbai - 400 001	Mumbai- 400 051
Scrip Code: 544293	Scrip Symbol: SURAKSHA

Dear Sir / Ma'am,

Sub: Outcome of the Board meeting held today i.e. Thursday, 05 February 2026

Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time

With further reference to our letter dated 27 January 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. on Thursday, 05 February 2026, has *inter alia*, considered and approved the unaudited (standalone and consolidated) financial results of the Company for the quarter and nine months ended 31 December 2025 along with Limited Review Report thereon, issued by the Statutory Auditors of the Company, enclosed herewith as **Annexure-A**.

The meeting of the Board of Directors commenced at **3.00 pm (IST)** and concluded at **4.25 pm (IST)**.

You are requested to kindly take the same on record.

For Suraksha Diagnostic Limited

Mamta Jain
Company Secretary & Compliance Officer

Encl: As above

Suraksha Diagnostic Limited

CIN: L85110WB2005PLC102265

Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town,

Kolkata-700 156, West Bengal, India

E-mail: investors@surakshanet.com | **Website:** www.surakshanet.com

Phone:(033) 6605 9750

MSKA & Associates LLP

(Formerly known as M S K A & Associates)
Chartered Accountants

Floor 4, Duckback House
41, Shakespeare Sarani
Kolkata 700017, INDIA

Independent Auditor's Review Report on unaudited Standalone financial results of Suraksha Diagnostic Limited for the quarter and year to date ended December 31, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Suraksha Diagnostic Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Suraksha Diagnostic Limited (hereinafter referred to as 'the Company') for the quarter ended December 31, 2025 and the year to-date results for the period from April 1, 2025 to December 31, 2025 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration Number - 105047W/W101187

Dipak Jaiswal
Dipak Jaiswal
Partner
Membership No.: 063682
UDIN:
26063682JDASFLS2
Place: Kolkata
Date: February 5, 2026



Suraksha Diagnostic Limited

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)

Website : www.surakshanet.com

Statement of unaudited standalone financial results for the quarter and nine month ended 31 December 2025

₹ in lakhs

Particulars	Quarter ended			Nine month ended		Year ended 31 March 2025 (Audited)
	31 December 2025 (Unaudited)	30 September 2025 (Unaudited)	31 December 2024 (Unaudited)	31 December 2025 (Unaudited)	31 December 2024 (Unaudited)	
Income						
I Revenue from operations	7,558.09	7,626.33	5,857.00	22,212.32	18,495.03	24,909.54
II Other income	98.66	96.72	97.45	304.95	344.09	438.30
III Total Income	7,656.75	7,723.05	5,954.45	22,517.27	18,839.12	25,347.84
IV Expenses						
Cost of materials consumed	857.65	880.38	598.82	2,606.83	2,035.65	2,894.54
Employee benefits expenses	1,303.31	1,298.98	1,101.42	3,843.77	3,191.06	4,190.58
Finance costs	309.86	271.76	203.29	847.47	632.20	838.53
Depreciation and amortisation expense	1,010.88	965.34	861.55	2,891.59	2,606.90	3,472.83
Impairment loss/(gain)	85.85	20.45	88.20	17.26	138.35	218.58
Other expenses	2,992.44	3,029.19	2,259.27	8,644.56	6,853.05	9,346.81
Total expenses (IV)	6,559.99	6,466.10	5,112.55	18,851.48	15,457.21	20,961.87
V Profit before tax and exceptional items (III-IV)	1,096.76	1,256.95	841.90	3,665.79	3,381.91	4,385.97
VI Exceptional items	-	-	-	-	-	-
VII Profit before tax (V-VI)	1,096.76	1,256.95	841.90	3,665.79	3,381.91	4,385.97
VIII Income tax expense						
(i) Current tax expense	239.35	308.49	215.41	833.51	882.30	1,066.83
(ii) Tax pertaining to earlier period/years	-	-	-	-	-	(38.22)
(iii) Deferred tax expense/(credit)	43.35	12.09	(9.20)	96.98	(43.72)	13.36
Total tax expense (VIII)	282.70	320.58	206.21	930.49	838.58	1,041.97
IX Profit for the period/year (VII-VIII)	814.06	936.37	635.69	2,735.30	2,543.33	3,344.00
X Other comprehensive income						
(a) Items that will not be reclassified subsequently to profit or loss						
(i) Remeasurement gain/(loss) of net defined benefit plan	12.72	(0.56)	16.35	38.16	(18.78)	(27.25)
(ii) Income tax effect on above	(3.20)	0.14	(4.11)	(9.60)	4.73	6.86
Other comprehensive income/(losses) for the period/year, net of tax	9.52	(0.42)	12.24	28.56	(14.05)	(20.39)
XI Total comprehensive income for the period/year	823.58	935.95	647.93	2,763.86	2,529.28	3,323.61
XII Paid-up equity share capital (face value - ₹ 2 per share)	1,041.62	1,041.62	1,041.62	1,041.62	1,041.62	1,041.62
XIII Other equity						20,389.60
XIV Earnings per equity share (Face Value of ₹ 2 each)						
- Basic (₹) (not annualised except for year end figures)	1.56	1.80	1.22	5.25	4.88	6.42
- Diluted (₹) (not annualised except for year end figures)	1.56	1.80	1.22	5.25	4.88	6.42



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com


Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

Notes to the unaudited standalone financial results

1. The unaudited standalone financial results for the quarter and nine months ended 31 December 2025 ("the financial results") of Suraksha Diagnostic Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").
2. These unaudited standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 05 February 2026. The statutory auditor have carried out limited review on these financial results and have issued an unmodified conclusion.
3. The Company is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 – Operating Segments'.
4. On 21 November 2025, the Government of India notified four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations under the New Labour Codes. The Company has assessed and the incremental impact of these changes, on the basis of the best information available for the period ended 31 December 2025, is not material to these financial results. The Management also continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the New Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
5. In a step-down subsidiary of the Company, an ongoing dispute with the Government of Meghalaya (the public partner) has resulted in operational losses. As a result, the recoverability of the Company's investments and loans advanced to subsidiary & trade receivables from step-down subsidiary, aggregating to ₹345.56 lakhs as at 31 December 2025 is under assessment. Based on the legal opinion obtained and management's assessment, the Company believes that the outcome of the on going proceedings will be in favour of the step-down subsidiary. Accordingly, no provision has been considered necessary in respect of the aforesaid matter in the unaudited standalone financial results for the quarter and period ended 31 December 2025.
6. These unaudited standalone financial results are also available on the Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseindia.com).
7. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.



For and on behalf of Board of Directors of
Suraksha Diagnostic Limited


Dr. Somnath Chatterjee
Chairman & Joint Managing Director
DIN: 00137075



Place: Kolkata
Date: 05 February 2026

Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

Independent Auditor's Review Report on unaudited consolidated financial results of Suraksha Diagnostic Limited for the quarter and year to date ended December 31, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Suraksha Diagnostic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Suraksha Diagnostic Limited (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended December 31, 2025 and the year-to-date results for the period from April 01, 2025 to December 31, 2025 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.



MSKA & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Suraksha Speciality LLP	Subsidiary
2	Asian Institute of Immunology & Rheumatology LLP (AIIR)	Subsidiary
3	Suraksha Radiology Private Limited	Subsidiary
4	Suraksha Advanced Radiology Private Limited	Subsidiary
5	Fetomat Wellness Private Limited	Subsidiary
6	Suraksha Salvia LLP	Step-down subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of six subsidiaries included in the Statement, whose interim financial statements reflects total revenues of INR 283.20 lakhs and INR 893.34 lakhs, total net loss after tax of INR 90.99 lakhs and INR 211.78 lakhs and total comprehensive income of INR (90.99) lakhs and INR (211.78) lakhs for the quarter ended December 31, 2025 and for the period from April 01, 2025 to December 31, 2025 respectively, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.



Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India

Tel: +91 22 6974 0200 | LLPIN: ACT-3789

Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Mumbai | Pune www.mskalp.com

MSKA & Associates LLP


(Formerly known as M S K A & Associates)

Chartered Accountants

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and reports of the other auditors.

M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants

ICAI Firm Registration Number - 105047W/W101187


Dipak Jaiswal

Partner

Membership No.: 061602

UDIN:

26063682MMLNY04876

Place: Kolkata

Date: February 5, 2026



Suraksha Diagnostic Limited

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)

Website : www.surakshanet.com

Statement of unaudited consolidated financial result for the quarter and nine month ended 31 December 2025

(₹ in lakhs)

Particulars	Quarter ended			Nine month ended		Year ended 31 March 2025 (Audited)
	31 December 2025 (Unaudited)	30 September 2025 (Unaudited)	31 December 2024 (Unaudited)	31 December 2025 (Unaudited)	31 December 2024 (Unaudited)	
Income						
I Revenue from operations	7,768.73	7,872.90	5,951.30	22,900.26	18,699.80	25,209.27
II Other income	62.16	85.14	59.91	237.87	302.92	384.60
III Total Income	7,830.89	7,958.04	6,011.21	23,138.13	19,002.72	25,593.87
IV Expenses						
Cost of materials consumed	866.62	890.08	610.32	2,631.75	2,067.11	2,951.91
Employee benefits expenses	1,341.86	1,339.16	1,128.66	3,958.49	3,268.69	4,289.03
Finance costs	315.69	277.58	198.15	863.76	632.20	838.53
Depreciation and amortisation expense	1,056.46	1,014.32	882.72	3,019.02	2,656.89	3,529.77
Impairment loss/(gain)	85.85	20.45	88.20	17.26	138.35	218.58
Other expenses	3,158.38	3,211.76	2,298.49	9,190.26	7,020.20	9,625.52
Total expenses (IV)	6,824.86	6,753.35	5,206.54	19,680.54	15,783.44	21,453.34
V Profit before tax and exceptional items (III-IV)	1,006.03	1,204.69	804.67	3,457.59	3,219.28	4,140.53
VI Exceptional items						
VII Profit before tax (V-VI)	1,006.03	1,204.69	804.67	3,457.59	3,219.28	4,140.53
VIII Income tax expense						
(i) Current tax expense	238.68	309.83	215.41	836.33	882.30	1,067.60
(ii) Tax pertaining to earlier years	(0.05)	-	-	(0.05)	(38.22)	(38.22)
(iii) Deferred tax expense/(credit)	43.35	12.09	(9.20)	96.98	(43.72)	13.36
Total tax expense (VIII)	281.98	321.92	206.21	933.26	838.58	1,042.74
IX Profit for the period/year (VII-VIII)	724.05	882.77	598.46	2,524.33	2,380.70	3,097.79
X Other comprehensive income						
(a) Items that will not be reclassified subsequently to profit or loss						
(i) Remeasurement gain/(loss) of net defined benefit plan	12.72	(0.56)	16.35	38.16	(18.78)	(27.25)
(ii) Income tax effect on above	(3.20)	0.14	(4.11)	(9.60)	4.73	6.86
Other comprehensive income/(losses) for the period/year, net of tax	9.52	(0.42)	12.24	28.56	(14.05)	(20.39)
XI Total comprehensive income for the period/year	733.57	882.35	610.70	2,552.89	2,366.65	3,077.40
XII Profit for the period/year attributed to						
Owners of the parent	752.29	898.64	615.36	2,590.67	2,443.54	3,182.41
Non- controlling interests	(28.24)	(15.87)	(16.90)	(66.34)	(62.84)	(84.62)
XIII Other comprehensive income for the period/year attributable to						
Owners of the parent	724.05	882.77	598.46	2,524.33	2,380.70	3,097.79
Non- controlling interests						
XIV Total comprehensive income for the period/year attributable to						
Owners of the parent	9.52	(0.42)	12.24	28.56	(14.05)	(20.39)
Non- controlling interests	-	-	-	-	-	-
XV Paid-up equity share capital (face value - ₹ 2 per share)	761.81	898.22	627.60	2,619.23	2,429.49	3,162.02
XVI Other equity (including non-controlling interest)	(28.24)	(15.87)	(16.90)	(66.34)	(62.84)	(84.62)
XVII Earnings per equity share (Face Value of ₹ 2 each)						
- Basic ₹ (not annualised except for year end figures)	1.44	1.73	1.18	4.97	4.69	5.97
- Diluted ₹ (not annualised except for year end figures)	1.44	1.73	1.18	4.97	4.69	5.97



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

Notes to the unaudited consolidated financial results

1. The unaudited consolidated financial results for the quarter and nine months ended 31 December 2025 ("the financial results") of Suraksha Diagnostic Limited ("the Holding Company") and its subsidiary (Holding company and subsidiaries together referred to as 'the group') have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the regulations").
2. These unaudited consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 05 February 2026. The statutory auditor have carried out limited review on these financial results and have issued an unmodified conclusion.
3. The Group is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 –'Operating Segments'.
4. On 21 November 2025, the Government of India notified four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations under the New Labour Codes. The Company has assessed and the incremental impact of these changes, on the basis of the best information available for the period ended 31 December 2025, is not material to these financial results. The Management also continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the New Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
5. These unaudited consolidated financial results are also available on the Holding Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseindia.com).
6. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.



For and on behalf of Board of Directors
Suraksha Diagnostic Limited

Dr. Somnath Chatterjee
Chairman & Joint Managing Director
DIN: 00137075

Place: Kolkata
Date: 05 February 2026

Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265